Using PBPK to link systemic PK to local delivery in the lung

Günther Hochhaus and Jürgen Bulitta

In collaboration with Rob Price, Jag Shur (Univ. of Bath) Mike Hindle (VCU)

PBPK MODELING FOR THE DEVELOPMENT AND APPROVAL OF LOCALLY ACTING DRUG PRODUCTS ASCPT Pre-Conference (Washington DC, March 13, 2019



Disclaimer

- Funding for part of this work (DPI formulations, in vitro characterizations and PK study) was made possible, in part, by the Food and Drug Administration through contracts HHSF223201110117A, HHSF223201610099C, HHSF223201300479A, and grant 1U01FD004950 (dissolution).
- Views expressed in this presentation do not necessarily reflect the official policies of the U.S. Food and Drug Administration,
- nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.

Topics related to Bioequivalence? dose, regional deposition, time? 10 - 60 % **Complete absorption Deposited in lun** from the lung Cl_{muc} Lung Mouth and pharynx Orally bioavailable Systemic Circ, fraction Absorption Liver from gut **Systemic** 40 - 90 % Swallowed side effects (reduced by spacer or mouth rinsing) First-pass **GI** tract inactivation 3


Actual Question of this research Project

Can PK (NCA, PBPK/semi-mechanistic models)

extract Information on :

- Dose
- Dissolution/Absorption





A-4.5 μm	Lactohale LH201 (20% %)	
B-3.8 μm	Lactohale LH230 (10%)	
C-3.7µm	Lactohale LH 3oo (2.5%)	
All Formulations: Respitose SV003 + 0.8% FP		

Study Outline

- Develop three DPI-FP formulations (R. Price/Jag Shur)
 - Same dose
 - Same dissolution rate
 - Difference in central to peripheral lung deposition.

- Characterize through in vitro experiments

- Ex throat dose (Mike Hindle)
- Cascade impactor profile
- Dissolution rate

- Perform PK (4 way cross-over, repeat one formulation)

- Inhalation profiles measured for each inhalation
- Intra-subject variability
- NCA, compartmental population PK modeling (PBPK)


Cascade Impactor Data

Mass deposition	Particle size (µm)	A- 4.5 μm	B- 3.8 μm	C -3.7 μm
Mass Median Aerodynamic Diameter		<mark>4.50</mark>	<mark>3. 8</mark>	<mark>3.7</mark>
Larger Particles	2.8 - 8.1 μm	12.5	14.4	11.5
Smaller Particles ^P (µg)	< 2.8 µm	4.8	9.4	8.1
Relative Ex Throat Dose (Anatomical Throat)	2	1	1.3	1.2

^c and ^P presumable representing central and peripheral lung deposition, respectively

Similar mass deposition on larger stages
Mass deposition on smaller stages was substantially smaller for A-4.5μm


Do formulations provide same absorption rate? In vitro dissolution and permeation



PK Study Design

- 4-way, cross-over, double blind
- 24 healthy volunteers
- Dose: 5 * 100 μg
- Record individual inhalation profiles
- Non-compartmental Analysis + Compartmental Analysis (population-PK)
- PBPK based evaluation of popPK results

Before dose normalization



Conclusion I: NCA/BE


Overall:

Before dose Normalization

• AUC and C_{max} : A # B = C

After Dose Normalization


- AUC: A=B=C
- C_{max}/Dose: A # B=C
- AUC: c/p Differences could not be shown
- **C**_{max}: c/p Differences ????



Lung related population mean PK parameter estimates

Parameters	A- 4.5 μm	B- 3.8 μm	C -3.7 μm	
Parameters	Mean (SE%)	Mean (SE%)	Mean (SE%)	
Absorption $t_{1/2}$ for central lung (h)	6.2	7.9	9.1	
Absorption t_1 peripheral lung (h)	0.241	0.114	0.096	
Absorbed dose - central lung (%)	6.4 (18.2%)	4.4 (19.9%)	4.8 (15.1%)	
Absorbed dose-peripheral lung	5.1 (13%)	9.9 (17%)	9.9 (11%)	
(%)				


PopPK parameters BE Approach



• B-3.8 μ m and C-3.7 μ m were bioequivalent for both F_c and F_p

 A-4.5 μm vs B-3.8 μm and A-4.5 μm vs. C-3.7 μm were not bioequivalent


Conclusion 2: Proposed New Methodology for PopPK BE testing




Can we explain PopPK results by PBPK?

- We Know from PopPK
 - peripheral and central dose
 - central and peripheral ka
- PBPK Parameters
 - Deposited dose (in vitro)
 - c/p ratio (MMAD)
 - Dissolution (MMAD, GSD)
 - Permeability

– caco-2-cells(isolated perfused lung



PBPK Approach



Deposition:



Subject related Inhalation profile In vitro:

- Ex-throat dose
- Cascade impactor

In silico Assessment: Deposition Modeling Output

- c/p ratio
- Regional doses

Dissolution: Subject related: Healthy/Patient In vitro:

- Solubility
- Particle Size
- Dissolution rates

In-silico

- Agglomeration factor
- Noyes-Brunner

Output

• Dissolution rate

Diffusion:

Subject related:

Surface Areas, Thickness In vitro:

Peff (caco-2)


In-silico

Ficks-law (scaling) ¹⁶

Output

Absorption rate

Absorption Profile: PopPK vs PBPK



MMAD= 3.8 µm, GSD=2.0

Dose: 54 mcg, **Preludium**


Surface area: 60.2 *10^4 cm²

Permeability Peff: 13.8*10^-3 cm/h (Eriksson) Fitted Parameter:

Solubility: 0.73 μg/ml (Literature =0.5-1.4 μg/ml)

Dose 25 mcg, Preludium Surface area: 1.00E+04 cm² Solubility: 0.73 µg/ml Fitted Parameter: Permeability: 0.7*10^-3 cm/h


Drug Concentration in Lining Fluid



Conclusion (Part 3)

- PBPK model appears to be able to describe central and peripheral absorption by considering dissolution and permeation.
- Slow central absorption due to lack of sink conditions and combined effects of dissolution and permeation.
- PBPK approach should be able to predict PK of formulations differing in regional deposition, dose and dissolution
- Can PBPK support NCA approach?

Is C_{max} sensitive to c/p ratio?



Conclusions

- NCA Analysis are able to answer relevant questions related to BE assessment of Inhalation drugs (at least for lipophilic corticosteroids)
 - Dose
 - Residence time
 - Regional deposition
- Clinical studies might not be necessary
- Work underlines that PK may be able to provide supportive information important for pulmonary bioequivalence assessment

Study teams



UF Team.

Jürgen Bulitta, Ph.D. San Mong-Jen Chen, Ph.D. Pha Yuanyuan Jiao, Ph.D. Brai Uta Schilling, Ph.D. Mut Sharvari Bhagwat, Ph.D. MD Abhinav Kurumaddali Jie

<u>UF Team</u>

Sandra Baumstein, Pharm.D Brandon Seay, MD Mutasim N Abu Hasan, MD Jie Shao

Elham Amini, Pharm. D. Ann Ross, MHA

FDA Team

Denise Conti, Ph.D. Renish Delvadia, Ph.D. Minori Kinjo, Ph.D. Bavna Saluja, Ph.D. Murewa Oguntimein, M.H.S.

- HHSF223201110117A, HHSF223201610099C, HHSF223201300479A
- 1U01FD004950

<u>UB</u>

Jag Shur, Ph.D. Robert Price, Ph.D.

<u>VCU</u>

Mike Hindle, Ph.D. Xiangyin Wei, Ph.D.